Some of the commonly used checkpoint inhibitors include Pembrolizumab (Keytruda), Nivolumab (Opdivo), Atezolizumab (Tecentriq), and Ipilimumab (Yervoy). These drugs target different checkpoints but share the common goal of enhancing the immune response against cancer cells.